ASCO 2022 | DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer

Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, provides his highlights in the field of breast cancer presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including highly anticipated results from the DESTINY-Breast04 trial (NCT03734029), which will potentially set the new standard of care in HER2-low breast cancer. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.